This phase I trial is trying to determine the dose of two combined oral therapies (ipatasertib and rucaparib) as a treatment for advanced breast, ovarian or prostate cancer
Status : Recruiting
This phase I/II trial is trying measure the dose of a new oral therapy (LOXO-305) as a treatment for people with Chronic Lymphocytic Leukaemia (CLL), Small Lymphocytic Leukaemia (SLL) or B-Cell Non-Hodgkin Lymphoma who have failed or unable to receive standard of care
This phase I trial is trying to measure the dose of a new oral therapy (JNJ-67856633) as a possible treatment for people with B-Cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukaemia, who have gotten worse or not responded to other treatments
This phase III trial is trying to determine how safe and effective the drug Uproleselan is, when given in combination with chemotherapy, in the treatment of Acute Myeloid Leukaemia that has gotten worse or not responded to prior therapy
This phase III trial is evaluating the safety and effectiveness of a type of immunotherapy (Pembrolizumab) alone and in combination with an oral targeted therapy (Lenvatinib) in patients who have received no prior treatment for metastatic non-small cell lung cancer
This phase III trial is trying to determine whether the combination of an immunotherapy (Durvalumab) and a standard of care therapy (Bacillus Calmette-Guerin) is better than giving standard of care therapy alone, in the treatment of non-muscle-invasive bladder cancer
This phase II trial is evaluating a biological therapy (Tavokinogene Telseplasmid - delivered by electroporation), in combination with an immunotherapy drug (Pembrolizumab), in patients with advanced triple negative breast cancer
This phase III trial is comparing the drug NKTR-102 with a treatment chosen by the doctor in patients who have have been treated for breast cancer that has spread to the brain
This phase III trial is comparing the effectiveness of a biological therapy (Axicabtagene Ciloleucel) and standard of care chemotherapy in Diffuse Large B-Cell Lymphoma patients who have gotten worse or not responded to prior treatment
This phase I trial is testing escalating doses of a new oral therapy (RP4010) in lymphoma patients who have gotten worse or not responded to prior treatment
Looking for a trial? Use the search functionality to find the trial you are finding.